Sign up for our daily briefing

Make your busy days simpler with the Axios AM and PM newsletters. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to the Axios Closer newsletter for insights into the day’s business news and trends and why they matter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios Pro Rata

Dive into the world of dealmakers across VC, PE and M&A with Axios Pro Rata. Delivered daily to your inbox by Dan Primack and Kia Kokalitcheva.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with the Axios Sports newsletter. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with the Axios Des Moines newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with the Axios Tampa Bay newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Nashville news?

Get a daily digest of the most important stories affecting your hometown with the Axios Nashville newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Columbus news?

Get a daily digest of the most important stories affecting your hometown with the Axios Columbus newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Dallas news?

Get a daily digest of the most important stories affecting your hometown with the Axios Dallas newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Austin news?

Get a daily digest of the most important stories affecting your hometown with the Axios Austin newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Atlanta news?

Get a daily digest of the most important stories affecting your hometown with the Axios Atlanta newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Philadelphia news?

Get a daily digest of the most important stories affecting your hometown with the Axios Philadelphia newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Chicago news?

Get a daily digest of the most important stories affecting your hometown with the Axios Chicago newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top DC news?

Get a daily digest of the most important stories affecting your hometown with the Axios DC newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!
Expand chart
Data: 46brooklyn Research; Chart: Naema Ahmed/Axios

The number of price increases on brand-name drugs fell by about half from 2015 through 2018, according to data provided to Axios and compiled by 46brooklyn Research, a nonprofit firm that tracks drug prices.

Yes, but: Several companies still raised list prices frequently and at rates well above inflation, and many medications that saw higher prices had already lost patent protection or are nearing a patent expiration.

Details: 46brooklyn previously studied generic pricing trends using federal data, and has since expanded to analyze federal data on brand-name drugs. A few caveats exist with its latest dataset:

  • The firm's analysis tracked list prices, and therefore doesn't include rebates and discounts that are paid to various middlemen. The industry hides those net prices as trade secrets.
  • Many high-cost drugs, like some cancer drugs and outpatient medicines, were not included in the analysis.

By the numbers: There are records of more than 10,000 drug price increases from 2015 through January 2019. But the pace of those price increases dropped once the calendar flipped to 2017.

  • No drug company raised prices more frequently than Pfizer. The company accrued more than 2,300 price hikes over the past 4 years and was recently caught in Trump's Twitter crosshairs before ultimately deciding to go back to the status quo.
  • Pfizer also has a lot of drugs on the market. After adjusting for the number of Pfizer's products, the company had about 23 price hikes per drug over the same time span, according to our own analysis of 46brooklyn's data. Pfizer responded by referring to a November statement that said prices for 2019 were unchanged for 90% of its drugs.
  • Other large drug makers that own a lot of medications — such as Allergan, Novartis and Johnson & Johnson — similarly raised prices hundreds of times since 2015.
  • Bristol-Myers Squibb had the most price hikes per drug (81.5), as the company raised prices multiple times on every dosage of two older drugs that have generic equivalents: Coumadin and Sustiva.
  • A BMS spokesperson said the company is committed "to fair pricing practices" and that net prices have not increased by more than 5% in any of the past five years. BMS also does "not plan to take increases on our mature medicines" in 2019.
  • Two other notable companies with high rates of per-drug price increases: AbbVie (32.6) and Purdue Pharma (28). AbbVie consistently raised the price of Humira, the world's top-selling drug. Purdue increased prices of a few drugs, including OxyContin, the controversial painkiller that has been tied closely to the opioid crisis.

The big picture: Although drug companies have slowed the number of price increases on their medicines due to the political climate, the industry at large is still raising prices with regularity, and that inevitably affects patients who have high deductibles and coinsurance rates.

  • We still don't know the net price companies are paid for their drugs, but their profits haven't taken a hit.

Go deeper: Explore the data.

Go deeper

Kate Marino, author of Markets
59 mins ago - Economy & Business

Omicron outbreaks were bad for business in January

Data: New York Federal Reserve Bank; Chart: Axios Visuals

Emerging anecdotal evidence shows just how hard the recent rise in COVID-19 cases hit businesses in early January — but that hasn't hurt some business leaders’ longer-term views on their companies' prospects.

Why it matters: Increasingly, the economic recovery has come in fits and starts that move in tandem with new peaks in cases. Look no further than the thousands of cancelled flights and shuttered Broadway theaters in the wake of the Omicron variant's spread over the last few months.

Tina Reed, author of Vitals
1 hour ago - Health

The shifting definition of fully vaccinated

Illustration: Sarah Grillo/Axios

The definition of what it means to be "fully vaccinated" is evolving even as the CDC has remained careful not to officially change it.

Why it matters: CDC officials have been balancing the job of convincing Americans who've already gotten two doses of the importance of boosters with getting many Americans who still need their first doses to get their shots at all.

Mike Allen, author of AM
2 hours ago - Economy & Business

Small businesses see hiring as No. 1 worry

Illustration: Aïda Amer/Axios

Almost every small business owner in a Goldman Sachs survey is having trouble hiring — and two-thirds think the federal government has done too little to ease their hiring, supply-chain and inflation worries.

Why it matters: The Goldman Sachs research gives a vivid window into the continuing headwinds and hardship for entrepreneurs.